CBRS vs GLUE
CBRS: Cerebras builds the world's fastest AI inference infrastructure powered by wafer-scale processors, enabling hyperscalers and enterprises to run large language models with near-instant responses. GLUE: Monte Rosa Therapeutics develops molecular glue degraders—a novel class of protein degradation drugs targeting historically undruggable proteins through its proprietary QuEEN discovery platform.
Side-by-side fundamentals
| Metric | CBRS | GLUE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $209.80 | $23.79 | |
| Market cap as of 2026-07-23 | $58.0B | $2.0B | |
| P/E as of 2026-07-23 | 243.71 | n/a | |
| Net margin as of 2026-07-23 | +46.6% | -302.7% | CBRS higher |
| Gross margin as of 2026-07-23 | +39.0% | n/a | |
| Operating margin as of 2026-07-23 | -28.6% | -345.2% | CBRS higher |
| ROE as of 2026-07-23 | +17.6% | -41.0% | CBRS higher |
| ROA as of 2026-07-23 | +10.2% | -25.9% | CBRS higher |
| Debt / equity as of 2026-07-23 | 0.36 | 0.00 | GLUE lower |
| Revenue growth (YoY) as of 2026-07-23 | +174.6% | -73.1% | CBRS higher |
| Beta as of 2026-07-23 | 6.54 | 1.49 | |
| 1-year return as of 2026-07-22 close | -33.0% | +305.3% | GLUE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.